Skip to main content
SpringerLink
Log in
Book cover

Controlled Substance Management in Chronic Pain pp 135–161Cite as

Complications of Opioid Therapy

  • Chapter
  • First Online:

  • 1002 Accesses

Abstract

Chronic pain is a major public health problem affecting about 30 % of the US population at an estimated $100 billion a year in medical costs, lost workdays, and compensation payments. The frequency and impact of chronic pain is expected to increase over the next decade. It is generally accepted that using accepted principles from the WHO for the management of non-cancer and cancer pain, when patients with moderate to severe pain do not get adequate pain relief from non-opioid analgesics, it often is appropriate to begin treatment with opioid analgesics and to continue to titrate the opioid analgesic medication in combination with non-opioids and adjuvants combined with non-pharmacological management treatments in attempt to control pain and suffering, improve function and quality of life.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Fishbain DA, Gallagher RM. Comments on “prescription drug dependence and evolving beliefs about chronic pain management”. Am J Psychiatry. 2006;163(12):2194–5.

    Google Scholar 

  3. Willy ME, Graham DJ, Racoosin JA, et al. Candidate metrics for evaluating the impact of prescriber education on the safe use of extended-release/long-acting (ER/LA) opioid analgesics. Pain Med. 2014;15(9):1558–68. doi:10.1111/pme.12459 Epub 2014 May 15.

    Article  PubMed  Google Scholar 

  4. Nersesyan H, Slavin KV. Current aproach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manage. 2007;3(3):381–400.

    CAS  Google Scholar 

  5. Ballantyne JC. Opioid controls: regulate to educate. Pain Med. 2010;11(4):480–1, 2 p. doi: 10.1111/j.1526-4637.2010.00822.x.

    Google Scholar 

  6. Ballantyne JC. Safe and effective when used as directed: the case of chronic use of opioid analgesics. J Med Toxicol. 2012;8(4):417–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dahan A, Overdyk F, Smith T, Aarts L, Niesters M. Pharmacovigilance: a review of opioid-induced respiratory depression in chronic pain patients. Pain Physician. 2013;16(2):E85–94.

    Google Scholar 

  8. Chou R, Turner JA, Devine EB, Hansen RN, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med. 2015;162(4):276–86. doi:10.7326/M14-2559.

    Article  PubMed  Google Scholar 

  9. Wang L, Wei X, Wang X, Li J, Li H, Jia W. Long-term effects of methadone maintenance treatment with different psychosocial intervention models. PLoS ONE. 2014;9(2):e87931.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Salvi F, Marchetti A, D’Angelo F, et al. Adverse drug events as a cause of hospitalization in older adults. Drug Safety. 2012;35 Suppl:29–45. 17p.

    Google Scholar 

  11. Model policy for the use of controlled substances for the treatment of pain. Dallas, Tex: federation of state medical boards of the United States, Inc; 2004. Available at: http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf.

  12. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74:102–12.

    Article  CAS  PubMed  Google Scholar 

  13. Flake ZA, Scalley RG, Bailey AG. Practical selection of antiemetics. Am Fam Physician. 2004;69:1169–74.

    PubMed  Google Scholar 

  14. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s the pharmacologic basis of therapeutics. 10th ed. New York, N.Y.: McGraw-Hill; 2001. p. 485–520.

    Google Scholar 

  15. Masui. Management of opioid-induced nausea and vomiting. 2013;62(7):829–35.

    Google Scholar 

  16. Ripamonti CI, Santini D, Maranzano E, Berti M, et al. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol October 1, 2012;23:vii139–54.

    Google Scholar 

  17. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25:442–53.

    Article  PubMed  Google Scholar 

  18. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Veder I, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350:2441–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sussman G, Shurman J, Creed MR, Larsen LS, Ferrer-Brechner T, Noll D, et al. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther. 1999;21:1216–27.

    Article  CAS  PubMed  Google Scholar 

  20. Canadian agency for drugs and technologies in health. Antiemetics for adults experiencing opioid-induced nausea: a review of clinical and cost effectiveness, benefits and harms and guidelines. [internet] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Apr. CADTH Rapid Response Reports.

    Google Scholar 

  21. Apfel CC, Jukar-Rao S. Is palonosetron also effective for opioid-induced and post-discharge nausea and vomiting? Br J Anaesth. 2012;108(3):371–3.

    Article  CAS  PubMed  Google Scholar 

  22. Moon HY, Baek CW, Choi GJ, Shin HY, et al. Palonsetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparascopic gynaecologic surgery: a doble-blind randomized trial. BMC Anesthesiol. 2014;14:68. doi: 10.1186/1471-2253-14-68. eCollection 2014.

  23. Yeh YC, Blouin GC, Reddy P. Evidence to support use of palonosetron over generic serotonin type 3–receptor antagonists for chemotherapy-induced nausea and vomiting. Am J Health-Syst Pharm. 2014;71:500–6.

    Article  CAS  PubMed  Google Scholar 

  24. Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;71:425–33.

    CAS  PubMed  Google Scholar 

  25. Kolesar JM, Eickhoff Jens, Vermeulen LC. Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? American Journal of Health-System Pharmacy. 2014;71(6):p507–10. 4p. 2 Charts. DOI: 10.2146/ajhp130653.

    Google Scholar 

  26. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347–54.

    PubMed  Google Scholar 

  27. Marciniak CM, Toledo S, Lee J, Jesselson M, Bateman J, Grover B, Tierny J. World J Gastroenterol. 2014;20(43):16323–33. doi:10.3748/wjg.v20.i43.16323.

    Article  PubMed  PubMed Central  Google Scholar 

  28. AGA technical review on constipation. Gastroenterology. 2000;119:1766.

    Article  Google Scholar 

  29. Aronoff GM: eds. Carr, Thomas. Medication management of chronic pain: what you need to know: management of opiate-induced constipation. Indiana, Trafford, 2015.

    Google Scholar 

  30. Lawrence R. Schiller: treatment of constipation and diarrhea. In: Wolfe MM, editor. Therapy of digestive disorders: a companion to Sleisenger and Fordtran’s gastrointestinal and liver disease. Philadelphia: WB Saunders; 2000. p. 747–55.

    Google Scholar 

  31. Fine PG. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med. 2012;13 Suppl 2:S57–66.

    Google Scholar 

  32. Foley KM, Houde RW: Methadone in cancer pain management: individualize dose and titrate to effect. J Clin Oncol. 1998;16:3213–15, (editorial).

    Google Scholar 

  33. Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manage. 2004;27:268–73.

    Article  PubMed  Google Scholar 

  34. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med. 1997;11(4):277–81.

    Article  CAS  PubMed  Google Scholar 

  35. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112(1):226–38.

    Article  PubMed  Google Scholar 

  36. McEvoy T, Moore J, Generali J. Inpatient prescribing and monitoring of fentanyl transdermal systems: adherence to safety regulations. Hosp Pharm. 2014;49(10):942–9. doi:10.1310/hpj4910-942.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Zedler B, Xie L, Wang L, Joyce A, et al. Risk factors for serious prescription opioid-related toxicity or overdose among veterans health administration patients. Pain Med. 2014;15(11):1911–29.

    Article  PubMed  Google Scholar 

  38. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Phys 2008 Opioid Spec Issue: 11:S105–20.

    Google Scholar 

  39. Gallagher R. Killing the symptom without killing the patient. Can Fam Physician. 2010;56(6):544–6, e210–12.

    Google Scholar 

  40. Boom M, Niester M, Sarton E, et al. Non-analgesic effects of opioids: opiod-induced respiratory depression. Curr Pharma Design. 5994–6004. http://www.eurekaselect.com/104017/article%20-%20sthash.b2qBpc8f.dpuf.

    Google Scholar 

  41. SAMHSA opioid overdose toolkit: information for prescribers. http://store.samhsa.gov/shin/content/SMA13-4742/Overdose_Toolkit_2014_Jan.pdf. Last accessed [February 23, 2015].

  42. van der Schier R, Roozekrans M, van Velzen M, et al. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep. 2014;6:79. doi: 10.12703/P6-79. eCollection 2014.

    Google Scholar 

  43. Golder FJ, Hewitt MW, McLeod JF. Respiratory stimulant drugs in the post-operative setting. Resp Physiol Neurobiol. 2013;189:395–402.

    Article  CAS  Google Scholar 

  44. Roozekrans M, van der Schrier R, Hoskins P, McLeod J, Dahan A. Doxapram reduces alfentanil plasma concentrations associated with an increase in cardiac output [abstract]. Anesthesiology. 2013;119:A3165.

    Google Scholar 

  45. Lötsch J, Skarke C, Schneider A, Hummel T, Geisslinger G. The 5-hydroxytriptamine 4 receptor agonist mosapride does antagonize morphine-induced respiratory depression. Clin Pharmacol Ther. 2005;78:278–87.

    Article  PubMed  Google Scholar 

  46. Oertel BG, Schneider A, Rohrbacher M, Schmidt H, Tegeder I, Geisslinger G, Lötsch J. The partial 5-hydroxytriptamine 1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans. Clin Pharmacol Ther. 2007;81:59–68.

    Article  CAS  PubMed  Google Scholar 

  47. Dahan A, Roozekrans M, van der Schrier R, Smith T, Aarts L. Primum non nocere or How to resolve drug-induced respiratory depression. Anesthesiology. 2013;118:1261–3.

    Article  PubMed  Google Scholar 

  48. Chidambaran V, Olbrecht V, Hossain M, Sadhasivam S, Rose J, Meyer MJ. Risk predictors of opioid-induced critical respiratory events in children: naloxone use as a quality measure of opioid safety. Pain Med. 2014;15(12):2139–49. doi:10.1111/pme.12575 Epub 2014 Oct 15.

    Article  PubMed  Google Scholar 

  49. Mujtaba S, Romero J, Taub CC. Methadone, QTc prolongation and torsades de pointes: current concepts, management and a hidden twist in the tale? J Cardiovasc Dis Res. 2013;4(4):229–35. doi:10.1016/j.jcdr.2013.10.001 Epub 2013 Nov 16.

    PubMed  PubMed Central  Google Scholar 

  50. Stallvik M, Nordstrand B, Kristensen Ø, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine—relation to doses and serum concentrations. Drug Alcohol Depend. 2013;129(1–2):88–93. doi:10.1016/j.drugalcdep.2012.09.016 Epub 2012 Oct 16.

    Article  CAS  PubMed  Google Scholar 

  51. Price LC, Wobeter B, Delate T, Kurz D, Shanahan R. Methadone for pain and the risk of adverse cardiac outcomes. J Pain Symptom Manage. 2014;48(3):333–42. e1. doi: 10.1016/j.jpainsymman.2013.09.021. Epub 2014 Jan 28.

    Google Scholar 

  52. Baker JR, Best AM, Pade PA, McCance-Katz EF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006;40(3):392–6 Epub 2006 Feb 28.

    Article  CAS  PubMed  Google Scholar 

  53. Kim CH, Garcia R, Stover J, Ritchie K, Whealton T, Ata MA. Androgen deficiency in long-term intrathecal opioid administration. Pain Physician. 2014;17(4):E543–8.

    Google Scholar 

  54. De Maddalena C, Bellini M, Berra M, et al. Opioid-induced hypogonadism: why and how to treat it. Pain Physician. 2012;15(3):ES111–8.

    Google Scholar 

  55. Awwad JT, Farra C, Mitri F, Abdallah MA, Jaoudeh MA, Ghazeeri G. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study.

    Google Scholar 

  56. https://www.aace.com/files/osteo-guidelines-2010.pdf. ACCE Medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. [Last accessed 03/02/2015].

  57. www.paulchristomd.com/wp…/flowhub/pdf/Opioid%20Effectiveness.pdf. [Last accessed 3/2/2015].

  58. Gooren LJ, Bunk MC. Androgen replacement therapy: present and future. Drugs. 2004;64(17):1861–91.

    Article  CAS  PubMed  Google Scholar 

  59. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9(1):28–36.

    Article  CAS  PubMed  Google Scholar 

  60. Santen FJ, Sofsky J, Bilic N, Lippert R, et al. Mechanism of action of narcotics in the production of menstrual dysfunction in women. Fertil Steril. 1975;26:538–48.

    Article  CAS  PubMed  Google Scholar 

  61. Kingsburg S, Shifren J, Wkselman K, et al. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2007;4(4 pt1):1001–1008.

    Google Scholar 

  62. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society [published online ahead of print September 1, 2005]. Menopause 2005;12;496–511.

    Google Scholar 

  63. Palacio S. Advances in hormone replacement therapy: making the menopause manageable. BMC Womens Health. 2008;8:22.

    Article  Google Scholar 

  64. Colameco S, Coren J. Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009;109:20–5.

    PubMed  Google Scholar 

  65. Benefits of DHEA: the master normone. Life extension web site. Available at: http://www.lef.org/dhea/benefits_of_dhea.htm. Last accessed 02/02/2015.

  66. Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency.

    Google Scholar 

  67. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998;49:4201–432.

    Article  Google Scholar 

  68. Katz N. The impact of opioids on the endocrine system. Pain Mange Rounds. 2005;1(9).

    Google Scholar 

  69. Folstein MF, Fetting JH, Lobo A, Niaz U, Capozzoli KD. Cognitive assessment of cancer patients. Cancer. 1983;53(suppl 10):2250–7.

    Google Scholar 

  70. Sjogren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage. 2000;19:100–8.

    Article  CAS  PubMed  Google Scholar 

  71. Vella-Brincat j, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J. Pain Palliative Care Pharmacother. 2007;21(1):15–25.

    Google Scholar 

  72. Ersek M, Cherrier MM, Overman SS, Irving GA. The cognitive effects of opioids. Pain Manage Nurs. 2004;5(2):75–93.

    Article  Google Scholar 

  73. Fishbain DA, Cutler B, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003;25(6):559–77.

    Article  PubMed  Google Scholar 

  74. Sabatowski R, Scharnagel R, Gyllensvärd A, Steigerwald I. Driving ability in patients with severe chronic low back or osteoarthritis knee pain on stable treatment with tapentadol prolonged release: a multicenter, open-label, phase 3b trial. Pain Ther. 2014;3(1):17–29. doi:10.1007/s40122-014-0025-3 Epub 2014 Apr 4.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Meijler WJ. Driving ban for patients on chronic opioid therapy unfounded. Ned Tijdschr Geneeskd. 2000;144:1644–5.

    CAS  PubMed  Google Scholar 

  76. Chapman SL, Byas-Smith MG, Reed BA. Effects of intermediate- and long-term use of opioids on cognition in patients with chronic pain. Clin. J. Pain. 2002;18(4 Suppl):S83–90.

    Google Scholar 

  77. Højsted J, Kurita GP, Kendall S, de Lundorff L, Mattos Pimenta CA, Sjøgren P. Non-analgesic effects of opioids: the cognitive effects of opioids in chronic pain of malignant and non-malignant origin. An update. Curr Pharm Des. 2012;18(37):6116–22.

    Article  PubMed  Google Scholar 

  78. Zaaijer ER, Bruijel J, Blanken P, Hendriks V, et al. Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. Drug Alcohol Depend. 2014;1(145):101–5. doi:10.1016/j.drugalcdep.2014.09.783 Epub 2014 Oct 14.

    Article  Google Scholar 

  79. White KT, Dillingham TR, González-Fernández M, Rothfield L. Opiates for chronic nonmalignant pain syndromes: can appropriate candidates be identified for outpatient clinic management? Am J Phys Med Rehabil. 2009;88(12):995–1001. doi:10.1097/PHM.0b013e3181bc006e.

    Article  PubMed  Google Scholar 

  80. Aronoff, GM eds. Bolen J. Medication management of chronic pain: use of controlled substances for pain management: a legal perspective Indiana: Trafford 2016.

    Google Scholar 

  81. Greaves MW, Wall PD. Pathophysiology of itching. Lancet. 1996;348:938–40.

    Article  CAS  PubMed  Google Scholar 

  82. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.

    Article  PubMed  Google Scholar 

  83. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage. 1998;16:121–4.

    Article  CAS  PubMed  Google Scholar 

  84. http://www.merckmanuals.com/professional/neurologic_disorders/pain/treatment_of_pain.html. [Last accessed 2/24/2015].

  85. Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther. 2007;82:48–53.

    Article  CAS  PubMed  Google Scholar 

  86. Malinovsky JM, Le Normand L, Lepage JY, Malinge M, Cozian A, Pinaud M, Buzelin JM. The urodynamic effects of intravenous opioids and ketoprofen in humans.

    Google Scholar 

  87. http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/pain/treatment_of_pain.html?qt=adverse%20effects%20opioids&alt=sh. [Last accessed 2/24/2015].

  88. Ikeda T, Kurz A, Sessler DI, et al. The effect of opioids on thermoregulatory responses in humans and the special an tishivering action of meperidine. Ann NY Acad Sci. 1997;813:792–8.

    Article  CAS  PubMed  Google Scholar 

  89. Al-Adwani A, Basu N. Methadone and excessive sweating [letter]. Addiction. 2004;99:259.

    CAS  PubMed  Google Scholar 

  90. Catterall RA. Problems of sweating and transfermal fentanyl. Palliat Med. 1997;11:169–70.

    CAS  PubMed  Google Scholar 

  91. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage. 2003;25:302–5.

    Article  PubMed  Google Scholar 

  92. Andrews HL. The effects of opiates on the pain threshold in post-addicts. J Clin Invest. 1943;22(4):511–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005;22:291–4.

    Article  PubMed  Google Scholar 

  94. De-Yong L, Shi Xiaoyou, Li Xianggi, et al. The β2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res. 2007;181(1):118–26.

    Article  Google Scholar 

  95. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med. 2009;10(5):829–39. doi: 10.1111/j.1526-4637.2009.00653.x. Epub 2009 Jul 6. Review.

    Google Scholar 

  96. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–3.

    Article  CAS  PubMed  Google Scholar 

  97. Lee M, Silverman S, Hansen H. A comprehensive review of opioid-induced. Hyperalgesia Pain Physician 2011;14:145–161.

    Google Scholar 

  98. Koppert W, Sittle R, Scheuber K, et al. Differential modulation of remifentanil-induced analgesia and post infusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99(1):152–9.

    Article  CAS  PubMed  Google Scholar 

  99. Tiseo PJ, Thaler HT, Lapin J et al: Morphine-6-Glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain. 1995;61(1):47–54. See more at: http://www.cancernetwork.com/oncology-journal/current-management-opioid-related-side-effects/page/0/3#sthash.j6HipfjC.dpuf.

    Google Scholar 

  100. McPherson ML. Strategies for management of opioid-induced adverse effects. Adv Stud Pharm. 2008;5(2):52–7.

    Google Scholar 

  101. Aronoff GM. Marijuana usage in chronic pain patients: driving and work guidelines for clinicians. Pain Medicine News. [epub]. 2013 June.

    Google Scholar 

  102. Marijuana as medicine: assessing the science base. National Academy Press, Washington, DC. 1999.

    Google Scholar 

  103. Jolly BT. Drugged driving—different spin on an old problem [Editorial]. Ann Emerg Med April 2000;35:399–400.

    Google Scholar 

  104. National Highway Traffic Safety Administration. Marijuana and alcohol combined severely impede driving performance. Ann Emerg Med. 2000;35:398–9.

    Google Scholar 

  105. Amar Ben. M. Cannaboids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25.

    Article  PubMed  Google Scholar 

  106. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannaboids: a systematic review. CMAJ. 2008;178(13):1669–78. doi: 10.1503/cmaj.071178.

    Google Scholar 

  107. Ashton CH. Pharmacology and the effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101–6.

    Article  CAS  PubMed  Google Scholar 

  108. Pesce, A, Ist, C, Rosenthal M, et al. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician. 2010;13(3):283–7.

    Google Scholar 

  109. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannaboids: a systematic review. CMAJ. 2008;178(13):1669–78. doi: 10.1503/cmaj.071178.

    Google Scholar 

  110. Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A Qual Syst Rev BMJ. 2001;323(7303):13–6.

    CAS  Google Scholar 

  111. Li G, Brady JE, Chenc Q. Drug use and fatal motor vehicle crashes: A case-control study. Accid Anal Prev. 2013;60:205–10.

    Article  PubMed  Google Scholar 

  112. Bolen, J. http://legalsideofpain.com/uploads/Marijuana-and-Your-Health-Just-The-Facts-Part-I.pdf.

  113. Sehgal N, Manchikanti, L, Smith HS. Prescription opioid abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician 2012;15:ES67–92.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pain Medicine, Carolina Pain Associates, PA, 1900 Randolph Road, Ste 1016, Charlotte, NC, 28207, USA

    Gerald M. Aronoff

Authors
  1. Gerald M. Aronoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald M. Aronoff .

Editor information

Editors and Affiliations

  1. Shrewsbury, New Jersey, USA

    Peter S. Staats

  2. Comprehensive Pain Medicine, Pompano Beach, Florida, USA

    Sanford M. Silverman

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Aronoff, G.M. (2016). Complications of Opioid Therapy. In: Staats, P., Silverman, S. (eds) Controlled Substance Management in Chronic Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-30964-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30964-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30962-0

  • Online ISBN: 978-3-319-30964-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation